184 related articles for article (PubMed ID: 34824604)
21. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
22. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
25. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.
Menegaz BA; Cuglievan B; Benson J; Camacho P; Lamhamedi-Cherradi SE; Leung CH; Warneke CL; Huh W; Subbiah V; Benjamin RS; Patel S; Daw N; Hayes-Jordan A; Ludwig JA
Oncologist; 2018 Mar; 23(3):360-366. PubMed ID: 29212731
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.
Nakano K; Motoi N; Tomomatsu J; Gokita T; Ae K; Tanizawa T; Matsumoto S; Takahashi S
BMC Cancer; 2016 Sep; 16(1):750. PubMed ID: 27663525
[TBL] [Abstract][Full Text] [Related]
27. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
29. Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma.
Liu J; Fan Z; Bai C; Li S; Xue R; Gao T; Zhang L; Tan Z; Fang Z
Ann Transl Med; 2021 Feb; 9(4):339. PubMed ID: 33708966
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
31. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
[TBL] [Abstract][Full Text] [Related]
32. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
34. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
[TBL] [Abstract][Full Text] [Related]
35. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
Matrana MR; Baiomy A; Campbell M; Alamri S; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Elsayes KM; Tannir NM
Clin Genitourin Cancer; 2017 Apr; 15(2):e205-e208. PubMed ID: 27568124
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib: in advanced soft tissue sarcoma.
Deeks ED
Drugs; 2012 Nov; 72(16):2129-40. PubMed ID: 23072642
[TBL] [Abstract][Full Text] [Related]
38. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
Mir O; Touati N; Lia M; Litière S; Le Cesne A; Sleijfer S; Blay JY; Leahy M; Young R; Mathijssen RHJ; Van Erp NP; Gelderblom H; Van der Graaf WT; Gronchi A
Clin Cancer Res; 2019 Mar; 25(5):1479-1485. PubMed ID: 30765389
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]